Graves' Disease

1. Clinical Overview

Graves' Disease is an organ-specific autoimmune disorder characterized by thyroid hyperfunction (thyrotoxicosis) resulting from stimulation of the thyroid-stimulating hormone receptor (TSHR) by thyroid-stimulating immunoglobulins (TSI), also known as TSH receptor antibodies (TRAb). [1,2]

Defining Features

Graves' Disease is distinguished from other causes of thyrotoxicosis by the presence of:

1. Diffuse thyroid hyperplasia (smooth, diffusely enlarged goitre)
2. Graves' Ophthalmopathy (Thyroid Eye Disease) - present in 25-50% of patients [3]
3. Pretibial myxoedema (dermopathy) - rare, less than 5% of cases [4]
4. Thyroid acropachy - very rare, less than 1% of cases [4]

Graves' Disease accounts for 60-80% of all cases of thyrotoxicosis in iodine-sufficient populations, making it the most common cause of sustained hyperthyroidism. [5]

Clinical Significance

• Peak incidence: 30-50 years of age
• Female predominance: 5-10:1 female-to-male ratio [6]
• Genetic susceptibility: 70% concordance in monozygotic twins [7]
• Recurrence risk: 30-50% relapse after initial medical treatment [8]

---

2. Epidemiology

Incidence and Prevalence

• Overall incidence: 20-50 cases per 100,000 person-years [6]
• Lifetime prevalence: 1-2% in women, 0.1-0.2% in men [6]
• Peak age: 30-50 years, with a second smaller peak in the elderly
• Geographic variation: Higher in iodine-sufficient regions [9]

Demographic Patterns

Age Distribution:

• Rare in children (less than 5% of paediatric thyrotoxicosis) [10]
• Predominantly affects young to middle-aged adults
• Increasing recognition in elderly patients (> 60 years), often with atypical presentations [11]

Sex Differences:

• Female-to-male ratio: 5-10:1 [6]
• Higher incidence in postpartum period (up to 6-fold increased risk in first year postpartum) [12]

Risk Factors

Genetic Factors:

• HLA associations: HLA-DR3 (Caucasians), HLA-B8, HLA-DQA1*0501 [7]
• Non-HLA genes: CTLA-4, PTPN22, CD40, TSHR, thyroglobulin [7]
• Family history: 30% have first-degree relative with autoimmune thyroid disease [7]

Environmental Triggers: [9]

• Smoking: Strong association (OR 1.9-7.7), particularly for ophthalmopathy development [13]
• Stress: Psychological stress may precipitate onset [9]
• Infection: Post-viral triggers proposed but not definitively proven [9]
• Iodine excess: High iodine intake can precipitate Graves' in susceptible individuals [9]
• Pregnancy/Postpartum: 6-fold increased risk in first postpartum year [12]
• Immune reconstitution: Risk with antiretroviral therapy, alemtuzumab, immune checkpoint inhibitors [14]

Associated Autoimmune Conditions:

• Type 1 Diabetes Mellitus (3-4% association)
• Pernicious anaemia
• Addison's disease (Schmidt syndrome)
• Vitiligo (7% association)
• Myasthenia gravis
• Coeliac disease [15]

---

3. Molecular Pathophysiology

TSH Receptor Structure and Function

The TSH receptor (TSHR) is a G-protein-coupled receptor located on thyroid follicular cells. [1] It consists of:

• Extracellular domain: TSH binding site, cleaved into A and B subunits
• Transmembrane domain: Seven transmembrane helices
• Intracellular domain: Coupled to Gs and Gq proteins

Normal Physiology:

• TSH binding → Gs activation → cAMP ↑ → Thyroid hormone synthesis
• TSH binding → Gq activation → Phospholipase C → Cell proliferation

Autoimmune Pathogenesis

Initiation Phase: [1,2]

1. Antigen presentation: Thyroid antigens presented to CD4+ T cells
2. Loss of tolerance: Breakdown of central and peripheral tolerance mechanisms
3. T cell activation: Th1 and Th2 helper T cell responses
4. B cell stimulation: Production of TSH receptor antibodies

Effector Phase:

TSH Receptor Antibodies (TRAb): [2]

Three functional types exist:

1. Stimulating antibodies (TSAb/TSI):

   • Bind to TSHR and activate cAMP pathway
   • Mimic TSH action → Unregulated thyroid hormone synthesis
   • Result in thyrotoxicosis and goitre
   • Persist for months to years

2. Blocking antibodies (TBAb):

   • Prevent TSH binding but do not activate receptor
   • Can cause hypothyroidism (seen in some Hashimoto's patients)
   • May coexist with stimulating antibodies

3. Neutral antibodies:

   • Bind TSHR but have no functional effect
   • May contribute to thyroid inflammation [16]

Thyroid Consequences:

• Follicular cell hypertrophy: Increased cell size and number
• Increased vascularity: Hypervascular gland (accounts for bruit)
• Unregulated hormone synthesis: ↑↑ T3 and T4 production
• Goitre formation: Diffuse gland enlargement (typically 2-3× normal size)

Extrathyroidal Manifestations

Graves' Ophthalmopathy (GO): [3,17]

The orbital manifestations result from:

1. TSHR expression: TSH receptors present on orbital fibroblasts and adipocytes
2. TRAb cross-reactivity: Antibodies activate orbital fibroblasts
3. Cytokine production: IL-1, TNF-α, IFN-γ drive inflammation
4. Glycosaminoglycan accumulation: Hyaluronic acid deposition in retro-orbital tissues
5. Adipogenesis: Orbital fat expansion
6. Fibrosis: Late-stage orbital tissue remodelling

Result: Increased retro-orbital volume → Proptosis, diplopia, optic nerve compression

Pretibial Myxoedema (Thyroid Dermopathy):

• TSHR expression on dermal fibroblasts
• Glycosaminoglycan accumulation in dermis
• Non-pitting oedema, typically pretibial [4]

Systemic Effects of Thyroid Hormone Excess

Cardiovascular:

• ↑ Cardiac output (increased stroke volume and heart rate)
• ↑ Myocardial oxygen consumption
• ↓ Systemic vascular resistance
• Risk of atrial fibrillation (10-25% of patients) [18]
• Risk of high-output heart failure

Metabolic:

• ↑ Basal metabolic rate (BMR) by 60-100%
• ↑ Protein catabolism → Muscle wasting
• ↑ Bone resorption → Osteoporosis risk [19]
• ↑ Hepatic gluconeogenesis
• ↑ Lipolysis

Neuromuscular:

• ↑ Sympathetic nervous system sensitivity
• ↑ Neuromuscular excitability
• Proximal myopathy (thyrotoxic myopathy)

---

4. Clinical Presentation

Symptoms of Thyrotoxicosis

Hypermetabolic State:

• Weight loss (typically 5-10 kg) despite normal or increased appetite [5]
• Heat intolerance and excessive sweating
• Fatigue and weakness (paradoxical despite hyperactivity)
• Increased bowel frequency (not frank diarrhoea usually)

Cardiovascular:

• Palpitations (sinus tachycardia > 100 bpm at rest is typical) [18]
• Dyspnoea on exertion
• Atrial fibrillation (particularly in elderly, "apathetic hyperthyroidism")
• Chest pain (rare, increased myocardial oxygen demand)

Neuropsychiatric:

• Nervousness, anxiety, emotional lability
• Tremor (fine tremor of outstretched hands)
• Insomnia
• Difficulty concentrating
• Hyperreflexia

Reproductive:

• Oligomenorrhoea or amenorrhoea in women
• Reduced fertility (both sexes)
• Erectile dysfunction in men
• Gynaecomastia in men (rare)

Musculoskeletal:

• Proximal muscle weakness (difficulty rising from chair, climbing stairs)
• Periodic paralysis (rare, predominantly in Asian males)

Signs on Examination

General Inspection:

• Anxious, hyperkinetic appearance
• Weight loss, muscle wasting
• Warm, moist skin
• Palmar erythema
• Onycholysis (Plummer's nails - separation of nail from nail bed)

Cardiovascular:

• Sinus tachycardia (resting HR typically 90-120 bpm)
• Atrial fibrillation (10-25% of cases) [18]
• Wide pulse pressure (elevated systolic, reduced diastolic BP)
• Systolic flow murmur (increased cardiac output)

Thyroid Gland:

• Diffuse, smooth, symmetrical enlargement (typically 2-3× normal size)
• Thyroid bruit - continuous hum over gland (indicates hypervascularity) [5]
• Non-tender (unlike subacute thyroiditis)
• May be asymmetric in 10-20% of cases

Graves'-Specific Features

1. Graves' Ophthalmopathy (GO) [3,17,20]

Present in 25-50% at diagnosis; develops before, concurrently, or after thyroid dysfunction

Clinical Activity Score (CAS): Used to assess inflammation (score 0-7)

• Pain (spontaneous or with eye movement)
• Redness (eyelid or conjunctival)
• Swelling (eyelid, caruncle, or conjunctival chemosis)

Severity Classification (EUGOGO):

• Mild: Minor impact on daily life

  • Lid retraction less than 2 mm
  • Mild soft tissue involvement
  • Exophthalmos less than 3 mm above normal
  • No diplopia or corneal exposure

• Moderate-to-Severe: Sufficient impact to justify immunosuppression

  • Lid retraction ≥2 mm
  • Moderate-severe soft tissue involvement
  • Exophthalmos ≥3 mm above normal
  • Inconstant or constant diplopia

• Sight-Threatening: Requires urgent intervention

  • Dysthyroid optic neuropathy (DON)
  • Corneal breakdown

Common Eye Signs:

1. Proptosis (Exophthalmos): [3]

   • Anterior displacement of globe > 20 mm (normal: 12-20 mm)
   • Bilateral in 90%, but often asymmetric
   • Due to increased retro-orbital volume

2. Lid retraction: [3]

   • Scleral show above cornea (visible white above iris)
   • Due to sympathetic overactivity (Müller's muscle) and inferior rectus fibrosis
   • Von Graefe's sign: Lid lag on downgaze

3. Periorbital oedema:

   • Puffy eyelids, worse on waking
   • Conjunctival injection and chemosis

4. Restrictive myopathy: [3]

   • Extraocular muscle enlargement (particularly inferior and medial recti)
   • Diplopia, initially vertical then horizontal
   • Limited upgaze most common

5. Optic neuropathy (3-5% of GO cases): [20]

   • Visual field defects
   • Reduced visual acuity
   • Colour vision impairment
   • Afferent pupillary defect
   • MEDICAL EMERGENCY - requires urgent high-dose steroids ± decompression

6. Corneal exposure:

   • Lagophthalmos (incomplete lid closure)
   • Risk of exposure keratopathy and ulceration

2. Pretibial Myxoedema (Thyroid Dermopathy) [4]

• Occurs in 1-5% of Graves' patients
• Almost always associated with ophthalmopathy
• Typically pretibial, but can occur on feet or arms

Appearance:

• Bilateral, asymmetric, non-pitting oedema
• Violaceous or skin-coloured plaques
• "Orange peel" or "peau d'orange" texture
• Nodular or plaque-like variants

3. Thyroid Acropachy [4]

• Rare (less than 1% of cases)
• Almost exclusively in patients with severe ophthalmopathy and dermopathy
• Digital clubbing with soft tissue swelling
• Periosteal new bone formation on X-ray (resembles hypertrophic osteoarthropathy)

---

5. Differential Diagnosis

Causes of Thyrotoxicosis

With Increased Radioiodine Uptake:

1. Graves' Disease (most common) [5]
2. Toxic Multinodular Goitre (second most common)
3. Toxic Adenoma (solitary autonomous nodule)
4. TSH-secreting pituitary adenoma (very rare)
5. Gestational thyrotoxicosis (hCG-mediated)
6. Familial non-autoimmune hyperthyroidism (activating TSHR mutation, rare)

With Decreased Radioiodine Uptake:

1. Subacute (De Quervain's) thyroiditis - painful gland
2. Silent (painless) thyroiditis - including postpartum thyroiditis
3. Drug-induced thyroiditis - amiodarone (type 2), lithium, interferon-α
4. Factitious thyrotoxicosis - exogenous thyroid hormone
5. Struma ovarii - ectopic thyroid tissue in ovarian teratoma (rare)

Key Differentiating Features

---

6. Investigations

Thyroid Function Tests

First-line: [5,21]

1. Serum TSH:

   • Suppressed (less than 0.01 mU/L typically)
   • Most sensitive test for primary hyperthyroidism
   • Remains suppressed for months after treatment initiation

2. Free T4 (fT4):

   • Elevated (typically > 30 pmol/L; normal 9-25 pmol/L)
   • Degree of elevation correlates with symptom severity

3. Free T3 (fT3):

   • Elevated (typically > 10 pmol/L; normal 3.5-7.8 pmol/L)
   • Often rises before T4 (more sensitive early marker)
   • T3 toxicosis: T3 elevated but T4 normal (5-10% of cases)

Severity Assessment:

• Subclinical thyrotoxicosis: Low TSH, normal fT4/fT3
• Overt thyrotoxicosis: Low TSH, elevated fT4 and/or fT3

Antibody Testing

TSH Receptor Antibodies (TRAb): [2,21]

• Sensitivity: 95-99% in active Graves' Disease
• Specificity: 99% for Graves' vs. other causes of thyrotoxicosis
• Clinical utility:
  • Confirms diagnosis (avoids need for radioiodine uptake scan in many cases)
  • Predicts relapse risk (persistently high TRAb = higher relapse risk)
  • Maternal monitoring in pregnancy (risk of fetal/neonatal thyrotoxicosis if high)
  • Distinguishes Graves' from painless thyroiditis

Thyroid Peroxidase Antibodies (TPO Ab):

• Positive in 75-80% of Graves' Disease
• Non-specific (also positive in Hashimoto's)
• Not required for diagnosis if TRAb positive

Thyroglobulin Antibodies (Tg Ab):

• Positive in 50-70% of Graves' Disease
• Non-specific, less useful diagnostically

Imaging and Nuclear Medicine

1. Thyroid Ultrasound: [21]

Not routinely required for diagnosis, but useful when:

• Palpable nodule present (assess for coexisting thyroid nodule/malignancy)
• Uncertainty about gland size
• Planning for radioiodine or surgery

Graves' sonographic features:

• Diffusely enlarged gland (typically 25-50 mL; normal 10-20 mL)
• Diffusely hypoechoic parenchyma
• Increased vascularity on Doppler ("thyroid inferno" pattern)

2. Radioiodine Uptake Scan (I-123 or Tc-99m): [5,21]

Indications:

• TRAb negative but clinical suspicion of Graves' remains
• Differentiate Graves' from thyroiditis or factitious thyrotoxicosis
• Pre-treatment planning for radioiodine therapy

Graves' scan features:

• Diffusely increased uptake (typically > 35% at 24 hours; normal 10-30%)
• Homogeneous distribution
• Uptake in pyramidal lobe may be seen

Comparison with other causes:

• Toxic nodule: Single area of increased uptake, suppressed surrounding tissue
• Toxic MNG: Multiple areas of increased uptake ("patchy")
• Thyroiditis: Decreased or absent uptake (less than 5%)

Adjunct Investigations

Complete Blood Count (CBC):

• Baseline before starting antithyroid drugs
• Monitor for agranulocytosis during treatment

Liver Function Tests:

• Baseline (antithyroid drugs can cause hepatotoxicity)

Calcium and Vitamin D:

• Check if planning radioiodine or surgery (parathyroid function assessment)

ECG:

• Identify atrial fibrillation (present in 10-25%) [18]
• Assess for ischaemia if cardiac symptoms

Bone Density Scan (DEXA):

• Consider if prolonged untreated hyperthyroidism (osteoporosis risk) [19]

---

7. Management

Treatment Goals

1. Normalise thyroid function (achieve euthyroidism)
2. Minimise treatment-related complications
3. Achieve long-term remission (if possible)
4. Manage extrathyroidal manifestations (ophthalmopathy, dermopathy)
5. Optimise quality of life

Initial Symptomatic Management

Beta-Blockers: [5,22]

First-line for symptom relief while awaiting antithyroid drug effect:

• Propranolol: 20-40 mg three times daily (preferred as it inhibits peripheral T4→T3 conversion)
• Atenolol: 25-100 mg once daily (alternative, more cardioselective)
• Metoprolol: 25-50 mg twice daily (alternative)

Indications:

• Tachycardia, palpitations
• Tremor, anxiety
• Heat intolerance

Contraindications:

• Asthma (use cardioselective if essential)
• Heart block, bradycardia
• Severe peripheral vascular disease

Duration: Continue until euthyroid on antithyroid drugs (typically 4-8 weeks), then taper

Definitive Treatment Modalities

Three options exist: Antithyroid drugs, Radioiodine, Surgery [5,21,22]

Choice depends on:

• Patient age and comorbidities
• Pregnancy status and future pregnancy plans
• Goitre size and compressive symptoms
• Ophthalmopathy presence and severity
• Patient preference

---

1. Antithyroid Drugs (ATD)

First-line treatment in most patients, particularly:

• Young patients (age less than 40 years)
• Mild-moderate disease
• Small goitres (less than 40 mL)
• First episode of Graves' Disease
• Pregnancy

Available Agents: [5,22]

• Thionamides:
  • "Carbimazole (UK, Europe): Pro-drug of methimazole, dose 5-40 mg daily"
  • "Methimazole (MMI) (US): Active drug, dose 5-30 mg daily"
  • "Propylthiouracil (PTU): Dose 50-150 mg three times daily"

Mechanism:

• Inhibit thyroid peroxidase (TPO) → Block iodine organification and thyroid hormone synthesis
• PTU additionally inhibits peripheral T4→T3 conversion
• Immunosuppressive effects (reduce TRAb levels over time)

Treatment Regimens:

A. Titration (Dose-Adjustment) Regimen: [22]

Initial phase (0-4 weeks):

• Carbimazole 20-40 mg daily (single morning dose)
• Higher doses (40 mg) for severe thyrotoxicosis (fT4 > 40 pmol/L)

Maintenance phase (after 4-6 weeks):

• Check TFTs every 4-6 weeks
• Reduce dose by 5-10 mg increments as fT4 normalises
• Target: Maintain on minimum dose to keep euthyroid (typically 5-10 mg daily)

Advantages:

• Lower total drug exposure
• Potentially fewer side effects

Disadvantages:

• Requires frequent monitoring
• Risk of hypothyroidism if dose not reduced appropriately
• TFTs can fluctuate

B. Block-and-Replace (B&R) Regimen: [22]

Protocol:

• Carbimazole 40 mg daily throughout
• Add levothyroxine 50-100 mcg daily once euthyroid (after 4-6 weeks)
• Adjust levothyroxine to maintain euthyroidism

Advantages:

• More stable thyroid function
• Less frequent monitoring (every 3 months)
• May improve quality of life

Disadvantages:

• Higher total drug exposure
• Cannot be used in pregnancy (see below)
• Potentially higher side-effect rate

Duration of Treatment: [8,22]

• Standard course: 12-18 months
• Longer courses (e.g., 24 months) do not improve remission rates
• Check TRAb levels before stopping (high levels predict relapse)

Remission Rates: [8]

• Overall remission: 40-60% remain in remission after stopping ATD
• Relapse: Typically occurs within first year (50% of relapses within 6 months)

Predictors of Remission:

• Small goitre (less than 40 mL)
• Mild biochemical thyrotoxicosis at diagnosis
• TRAb negative or low at end of treatment
• Young age
• Non-smoker

Predictors of Relapse:

• Large goitre (> 40 mL)
• High TRAb levels (> 6 U/L) at end of treatment
• Male sex
• Severe biochemical thyrotoxicosis at diagnosis
• Smoking

Monitoring During Treatment: [22]

TFTs:

• Every 4-6 weeks initially (titration regimen)
• Every 3 months once stable (block-and-replace)
• TSH may remain suppressed for months (do not use as sole guide)

FBC:

• Baseline before starting
• Not routinely repeated unless symptoms develop
• Urgent FBC if sore throat, fever, mouth ulcers (agranulocytosis)

LFTs:

• Baseline
• Repeat if symptoms of hepatotoxicity (jaundice, abdominal pain)

Side Effects: [23]

Common (5-15%):

• Pruritus, rash (maculopapular)
• Arthralgia
• GI upset (nausea)
• Headache

Management: Antihistamines for itch; switch thionamide (carbimazole ↔ PTU) if persistent

Rare but Serious (less than 1%):

1. Agranulocytosis (0.2-0.5%): [23,24]

• Definition: Absolute neutrophil count less than 0.5 × 10⁹/L
• Time to onset: Typically first 3 months (90% within first 6 months)
• Dose-dependent: Higher risk with PTU than carbimazole
• Presentation: Fever, sore throat, mouth ulcers, malaise

Patient Education (CRITICAL):

"If you develop a sore throat, fever, or mouth ulcers, STOP the medication immediately and attend for an urgent blood count within 24 hours."

Management if agranulocytosis occurs:

• Stop thionamide immediately and permanently
• Urgent haematology review
• G-CSF (granulocyte colony-stimulating factor) if severe
• Antibiotics if infection present
• Do not switch to other thionamide (cross-reactivity risk)
• Definitive treatment with radioiodine or surgery once recovered

Mortality: 5-10% if untreated/delayed recognition

2. Hepatotoxicity:

• PTU: Cholestatic or hepatocellular injury (more common, can be severe)
• Carbimazole/MMI: Typically cholestatic (less severe)
• Monitor LFTs if jaundice or abdominal pain develops
• Stop drug if ALT > 3× upper limit of normal

3. Vasculitis (PTU > carbimazole):

• ANCA-positive vasculitis
• Rash, arthralgia, haematuria, renal impairment

Pregnancy Considerations:

See Section 9 (Pregnancy and Graves' Disease)

---

2. Radioiodine (RAI) Therapy

Indications: [5,21,22]

• First-line in:

  • Adults > 40 years (particularly if no future pregnancy plans)
  • Relapse after antithyroid drug course
  • Non-compliance with medical therapy
  • Contraindication to antithyroid drugs (e.g., agranulocytosis)

• Alternative in:

  • Patient preference (definitive treatment)
  • Comorbidities making surgery high-risk

Contraindications (Absolute):

• Pregnancy (teratogenic and ablates fetal thyroid)
• Breastfeeding (radioiodine secreted in breast milk)
• Uncontrolled thyrotoxicosis (risk of thyroid storm post-RAI, rare)

Contraindications (Relative):

• Active/severe Graves' ophthalmopathy (risk of worsening eye disease) [25]
• Moderate ophthalmopathy (if RAI given, co-administer prophylactic glucocorticoids)
• Large goitre with compressive symptoms (swelling post-RAI may worsen compression)
• Young age (less than 18 years, though not absolute)
• Planning pregnancy within 6 months (women should delay 6 months; men 4 months)

Radioiodine Isotope:

• Iodine-131 (I-131): Beta-emitter with 8-day half-life
• Typically administered as oral capsule (200-600 MBq dose)

Mechanism:

• I-131 taken up by hyperactive thyroid tissue
• Beta radiation destroys thyroid follicular cells over 2-6 months
• Gradual decline in thyroid function

Pre-treatment Preparation:

1. Antithyroid drugs:

   • Stop 3-7 days before RAI (to allow iodine uptake)
   • Restart 3-7 days after RAI if thyrotoxicosis severe (to avoid post-RAI thyrotoxicosis)
   • Stop permanently 4-6 weeks after RAI

2. Beta-blockers: Continue throughout (symptom control)

3. Pregnancy test: Mandatory in women of childbearing age

4. TRAb levels: If planning pregnancy soon (high TRAb risk for fetal thyrotoxicosis)

5. Ophthalmology assessment: If any eye symptoms

Post-RAI Management:

Short-term (First 3 months):

• Avoid close contact with pregnant women and young children (first 7-14 days)
• Monitor for worsening thyrotoxicosis (transient, in first 2 weeks)
• Monitor for radiation thyroiditis (tender gland, rare)

Long-term:

• TFTs: Check at 4-6 weeks, then every 6-8 weeks until stable
• Hypothyroidism (expected outcome):
  • Develops in 80-90% within first year [26]
  • May occur months to years after treatment
  • Start levothyroxine when TSH > 10 mU/L or symptomatic
  • Lifelong thyroid hormone replacement required

Success Rates:

• Single dose: 70-90% cure rate [26]
• Second dose: Required in 10-30% if persistent hyperthyroidism at 6 months

Ophthalmopathy and RAI: [25]

• RAI can worsen or precipitate Graves' ophthalmopathy in 15-20% of cases
• Mechanism: Release of thyroid antigens → Increased immune response

Risk factors for RAI-induced ophthalmopathy worsening:

• Active ophthalmopathy (CAS > 3)
• Smoking (most important modifiable risk factor)
• Post-RAI hypothyroidism (if not corrected promptly)
• High TRAb levels

Mitigation strategies:

• Prophylactic glucocorticoids (if mild-moderate ophthalmopathy):
  • Prednisolone 0.3-0.5 mg/kg daily for 1 month, then taper over 3 months
  • Reduces risk of ophthalmopathy progression by 60% [25]
• Avoid RAI if severe active ophthalmopathy (CAS > 3) → Use surgery instead
• Ensure prompt correction of hypothyroidism post-RAI
• Smoking cessation (ESSENTIAL)

---

3. Thyroid Surgery (Thyroidectomy)

Indications: [5,21,22]

• Large goitre (> 80 mL) with compressive symptoms (dysphagia, dyspnoea, stridor)
• Coexisting suspicious thyroid nodule (concern for malignancy)
• Severe or progressive Graves' ophthalmopathy (RAI contraindicated)
• Pregnancy (second trimester if antithyroid drugs contraindicated/failed)
• Patient preference (desire for rapid definitive cure)
• Contraindication to RAI and antithyroid drugs

Types of Surgery:

Total Thyroidectomy (preferred): [27]

• Removal of entire thyroid gland
• Eliminates risk of recurrent hyperthyroidism
• Requires lifelong levothyroxine

Near-Total/Subtotal Thyroidectomy (now less common):

• Leaves small thyroid remnant (1-2 g)
• Recurrence risk: 5-10%

Pre-operative Preparation:

1. Achieve euthyroidism: [22]

   • Essential to reduce perioperative thyroid storm risk
   • Continue antithyroid drugs until euthyroid (typically 6-12 weeks)
   • Can proceed if subclinical but not overt thyrotoxicosis

2. Beta-blockade:

   • Propranolol 40 mg TDS for at least 7 days pre-operatively

3. Iodine preparation (optional):

   • Lugol's iodine 5-10 drops TDS for 10 days pre-op
   • Reduces gland vascularity (fewer intraoperative bleeding)
   • Risk: Jod-Basedow phenomenon (iodine-induced thyrotoxicosis worsening) if used too long

Complications of Surgery:

Immediate/Early (less than 1 week):

1. Bleeding/Haematoma (1-2%):

   • Can cause airway compromise (surgical emergency)
   • Presents with neck swelling, dyspnoea, stridor

2. Hypocalcaemia (transient 10-30%, permanent 1-3%):

   • Due to hypoparathyroidism (parathyroid gland injury/removal)
   • Transient: Recovers within 6 months
   • Permanent: Requires lifelong calcium and vitamin D (calcitriol)
   • Symptoms: Perioral paraesthesia, Chvostek's sign, Trousseau's sign, tetany

Late (> 1 week):

3. Recurrent Laryngeal Nerve (RLN) Injury (transient 3-5%, permanent 1-2%):

   • Unilateral: Hoarse voice, weak voice, aspiration risk
   • Bilateral: Stridor, respiratory compromise (requires tracheostomy)
   • Transient: Recovers within 6 months
   • Permanent: May require vocal cord medialisation or speech therapy

4. Hypothyroidism (> 99% after total thyroidectomy):

   • Expected outcome
   • Start levothyroxine 1.6 mcg/kg daily immediately post-op
   • Monitor TSH at 6 weeks, then every 3-6 months

Advantages of Surgery over RAI:

• Rapid definitive cure (euthyroid within days)
• No radiation exposure
• No risk of worsening ophthalmopathy
• Can address compressive symptoms

Disadvantages:

• Surgical risks (bleeding, RLN injury, hypoparathyroidism)
• Requires general anaesthesia
• Scar (though typically cosmetically acceptable)
• Longer recovery time vs. RAI

Outcomes: [27]

• Success rate: > 95% cure (total thyroidectomy)
• Recurrence: less than 5% (if near-total thyroidectomy, higher if subtotal)
• Mortality: less than 0.1% (experienced surgeon in euthyroid patient)

---

Treatment Algorithm Summary

┌──────────────────────────────────────────────────────────────┐
│                   NEWLY DIAGNOSED GRAVES' DISEASE             │
└──────────────────────────────────────────────────────────────┘
                            ↓
        ┌───────────────────────────────────────┐
        │    SYMPTOM CONTROL: Beta-blockers      │
        │    (Propranolol 40mg TDS)             │
        └───────────────────────────────────────┘
                            ↓
        ┌───────────────────────────────────────────────────┐
        │  DEFINITIVE TREATMENT - Three Options:            │
        └───────────────────────────────────────────────────┘
                            ↓
        ┌───────────────┬──────────────┬──────────────────┐
        │               │              │                  │
   [1] ATD        [2] Radioiodine  [3] Surgery
  (12-18m)          (I-131)       (Thyroidectomy)
        │               │              │
        ↓               ↓              ↓
   Remission        Hypothyroid    Hypothyroid
   40-60%            (80-90%)       (> 99%)
        │               │              │
        ↓               ↓              ↓
   Relapse        Levothyroxine   Levothyroxine
   40-60%          (Lifelong)      (Lifelong)
        │
        ↓
   RAI or Surgery
   (Definitive)

Choice of Initial Treatment: [5,21]

---

8. Graves' Ophthalmopathy (GO) Management

Graves' Ophthalmopathy (Thyroid Eye Disease) is the most common extrathyroidal manifestation, significantly impacting quality of life. [3,17,20]

Assessment

Clinical Activity Score (CAS): [20]

Seven features, score 1 point for each present (maximum 7):

1. Spontaneous retrobulbar pain
2. Pain on eye movement
3. Eyelid erythema
4. Eyelid oedema
5. Conjunctival injection (redness)
6. Chemosis (conjunctival oedema)
7. Caruncle/plica swelling

Interpretation:

• Active ophthalmopathy: CAS ≥3 (inflammatory phase, responds to immunosuppression)
• Inactive ophthalmopathy: CAS less than 3 (fibrotic phase, requires surgery if severe)

Severity Grading (EUGOGO): [20]

• Mild: Minor impact on QoL, no indication for immunosuppression
• Moderate-to-Severe: Sufficient impact to justify immunosuppression
• Sight-threatening: Dysthyroid optic neuropathy (DON) or severe corneal exposure

Management Principles

1. Ensure Euthyroidism: [20]

• Both hyper- and hypothyroidism worsen ophthalmopathy
• Maintain TSH in normal range (0.4-4.0 mU/L)
• Prompt correction of post-RAI hypothyroidism essential

2. Smoking Cessation: [13,20]

• Most important modifiable risk factor
• Smoking increases GO risk 8-fold
• Worsens severity and reduces treatment efficacy
• Mandatory advice for all patients

3. Selenium Supplementation: [28,29]

Evidence from randomised trials:

• Dose: 100 mcg twice daily for 6 months
• Efficacy: Mild-moderate benefit in mild GO (reduces progression, improves QoL)
• Mechanism: Antioxidant, reduces thyroid inflammation
• Note: Benefit primarily in selenium-deficient populations; less clear in selenium-sufficient areas [29]

Treatment by Severity

Mild GO: [20]

• Euthyroidism maintenance
• Smoking cessation
• Selenium 100 mcg BD for 6 months (consider)
• Artificial tears (lubricants for dry eyes)
• Sunglasses (photophobia)
• Prisms (if mild diplopia)
• Monitor: 3-6 monthly (watch for progression)

Moderate-to-Severe Active GO (CAS ≥3): [20]

First-line: Intravenous Glucocorticoids

• Regimen: IV methylprednisolone
  • 500 mg weekly × 6 weeks, then 250 mg weekly × 6 weeks
  • "Total cumulative dose: 4.5 g over 12 weeks"
• Efficacy: 70-80% response rate
• Superior to oral prednisolone (better efficacy, fewer side effects)

Monitoring during IV steroids:

• LFTs weekly (risk of hepatotoxicity)
• Blood glucose (hyperglycaemia)
• Blood pressure (hypertension)
• Bone protection (calcium, vitamin D; consider bisphosphonate if prolonged)

Second-line (if steroids ineffective/contraindicated):

• Orbital radiotherapy (20 Gy over 10 fractions) - adjunct to steroids or alone
• Mycophenolate mofetil (steroid-sparing agent)
• Tocilizumab (anti-IL-6 receptor antibody, emerging evidence)
• Teprotumumab (anti-IGF-1 receptor antibody, approved in US, not yet widely available) [20]

Sight-Threatening GO:

Dysthyroid Optic Neuropathy (DON): [20]

Presentation:

• Reduced visual acuity
• Colour vision defects (red desaturation)
• Visual field defects (central scotoma)
• Afferent pupillary defect (RAPD)
• Optic disc swelling or pallor

Management (URGENT):

• High-dose IV methylprednisolone: 1 g daily × 3 days, then taper
• Urgent orbital decompression surgery if no response to steroids within 48 hours
• Ophthalmology referral (same-day)

Severe Corneal Exposure:

• Lubricating ointments (frequent)
• Taping eyelids at night
• Urgent tarsorrhaphy (surgical lid closure) if corneal ulceration

Surgical Rehabilitation (Inactive GO)

Once disease inactive (CAS less than 3) for ≥6 months and euthyroid:

Sequence of surgery: [20]

1. Orbital decompression (if proptosis/optic neuropathy)
2. Strabismus surgery (if persistent diplopia)
3. Eyelid surgery (if lid retraction/lagophthalmos)

---

9. Graves' Disease in Pregnancy

Pregnancy presents unique challenges in Graves' Disease due to:

• Teratogenic risks of antithyroid drugs
• Risks of fetal/neonatal thyrotoxicosis (TRAb crosses placenta)
• Altered thyroid physiology in pregnancy [30,31]

Physiological Changes in Pregnancy

• hCG: Mild TSH-like effect (can cause transient gestational thyrotoxicosis in first trimester)
• TBG: Increases (total T4↑, but free T4 normal)
• Thyroid hormone requirements: Increase by 30-50%

Antithyroid Drug Choice in Pregnancy

First Trimester: [30,31]

Propylthiouracil (PTU) preferred

Reason:

• Carbimazole/methimazole: Associated with congenital abnormalities

  • Aplasia cutis (scalp defect)
  • Choanal/oesophageal atresia
  • Omphalocele
  • "Risk: ~2-4% (low but significant)"

• PTU: Lower teratogenic risk (though not zero; associated with urinary tract abnormalities, rare)

Dose: PTU 50-150 mg TDS (use lowest effective dose)

Second and Third Trimesters: [30,31]

Switch from PTU to Carbimazole/Methimazole

Reason:

• PTU: Risk of severe hepatotoxicity with prolonged use
• Carbimazole: Teratogenic risk limited to first trimester (organogenesis period)

Dose: Carbimazole 5-15 mg daily (use lowest effective dose)

Rationale for switch:

• First trimester organogenesis complete by 10 weeks
• Carbimazole safer long-term vs. PTU hepatotoxicity

Important: Block-and-replace regimen CONTRAINDICATED in pregnancy

• Levothyroxine crosses placenta poorly
• Carbimazole crosses readily → Fetal hypothyroidism if mother on B&R

Monitoring in Pregnancy

TFTs: [30,31]

• Every 2-4 weeks (more frequent than non-pregnant)
• Target: Upper limit of trimester-specific reference range (to minimise fetal exposure to ATD)
  • "First trimester: fT4 upper limit ~18-20 pmol/L"
  • "Second/third trimester: fT4 upper limit ~16-18 pmol/L"
• TSH: May remain suppressed throughout (not sole guide)

TRAb Levels: [30,31]

• Check at diagnosis/booking
• Repeat at 18-22 weeks and 30-34 weeks
• If TRAb high (> 3× upper limit of normal):
  • Risk of fetal/neonatal thyrotoxicosis
  • Requires fetal monitoring (ultrasound for goitre, growth, heart rate)
  • Neonatology alert for postnatal monitoring

Fetal Monitoring:

• Serial ultrasound (if high maternal TRAb):
  • Fetal goitre
  • Fetal tachycardia (HR > 170 bpm suggests fetal thyrotoxicosis)
  • Hydrops fetalis (severe cases)

Maternal Complications

• Thyroid storm (rare, precipitated by labour, infection, pre-eclampsia)
• Pre-eclampsia (2-3× increased risk if uncontrolled thyrotoxicosis)
• Preterm labour
• Heart failure (if severe thyrotoxicosis)

Fetal and Neonatal Complications

Fetal Thyrotoxicosis: [31,32]

• Due to transplacental passage of maternal TRAb
• Risk highest if maternal TRAb > 5× upper limit of normal
• Signs: Tachycardia (HR > 170 bpm), IUGR, goitre, advanced bone age
• Treatment: Increase maternal ATD dose (treats fetal thyrotoxicosis)

Neonatal Thyrotoxicosis: [32]

• Occurs in 1-5% of infants born to mothers with Graves' (past or present)
• Onset: Day 3-10 of life (delayed as maternal ATD wears off)
• Presentation: Irritability, poor feeding, tachycardia, goitre, failure to thrive
• Duration: Transient (resolves in 3-12 weeks as maternal TRAb clears)
• Treatment: Antithyroid drugs (carbimazole or PTU), beta-blockers, supportive care

Monitoring: All infants of mothers with Graves' require neonatal TFTs and clinical monitoring

Radioiodine and Pregnancy

• Absolutely contraindicated (teratogenic, ablates fetal thyroid from 10 weeks)
• Avoid pregnancy for 6 months after RAI (women) or 4 months (men)
• Mandatory pregnancy test before RAI administration

Surgery in Pregnancy

• Reserved for:

  • Severe disease unresponsive to ATD
  • Agranulocytosis from ATD
  • Compressive goitre symptoms

• Optimal timing: Second trimester (14-26 weeks)

  • "First trimester: Risk of miscarriage from anaesthesia"
  • "Third trimester: Risk of preterm labour"

Postpartum Period

• Worsening thyrotoxicosis common (immune rebound after pregnancy-induced immunosuppression)
• Adjust ATD dose accordingly
• Breastfeeding: Compatible with PTU or carbimazole (low levels in breast milk)
  • Carbimazole preferred (lower transfer than PTU)
  • Take dose after breastfeed to minimise infant exposure
• Neonatal monitoring: For thyrotoxicosis (see above)

---

10. Complications and Emergency Management

Thyroid Storm (Thyrotoxic Crisis)

A life-threatening exacerbation of thyrotoxicosis with multi-organ decompensation. [5,33]

Incidence:

• Rare (less than 1% of thyrotoxic patients)
• Mortality: 10-30% even with treatment [33]

Precipitants:

• Surgery (particularly if inadequately prepared)
• Infection (pneumonia, UTI, sepsis)
• Trauma
• Diabetic ketoacidosis
• Acute iodine load (contrast, amiodarone)
• Pregnancy/labour/delivery
• Abrupt cessation of antithyroid drugs
• Radioiodine therapy (very rare)

Clinical Features: [33]

Burch-Wartofsky Scoring System:

Interpretation:

• ≥45: Highly suggestive of thyroid storm
• 25-44: Impending storm
• less than 25: Unlikely

Key Diagnostic Features:

• Hyperpyrexia (> 39°C, often > 40°C)
• Severe tachycardia (HR > 140 bpm) ± atrial fibrillation
• Altered mental status (agitation, delirium, psychosis, seizures, coma)
• GI symptoms (vomiting, diarrhoea, abdominal pain, jaundice)
• Cardiovascular collapse (heart failure, shock)

Management (ICU/HDU): [33]

A. Resuscitation:

• Airway, breathing, circulation (ABC)
• IV fluids: Aggressive (dehydration from hyperpyrexia)
• Cooling: Paracetamol, cooling blankets (avoid aspirin - displaces T4 from binding proteins)
• Treat precipitant: Antibiotics if infection, insulin if DKA

B. Block Thyroid Hormone Synthesis:

1. Thionamide (high-dose):
   • PTU: 200 mg PO/NG 4-6 hourly (preferred as it also blocks T4→T3 conversion)
   • Carbimazole: 20 mg PO/NG 6 hourly (alternative)
   • Rectal administration if oral route not possible

C. Block Thyroid Hormone Release:

2. Iodine (give at least 1 hour after thionamide):
   • Lugol's iodine: 10 drops (0.5 mL) PO TDS
   • Potassium iodide: 500 mg PO TDS
   • Sodium iodide: 500 mg IV over 30 min (if oral route unavailable)

Rationale for delay: Iodine given before thionamide can worsen thyrotoxicosis (Jod-Basedow phenomenon)

D. Block Peripheral T4→T3 Conversion:

3. High-dose beta-blocker:

   • Propranolol: 40-80 mg PO 4-6 hourly (also blocks conversion)
   • Esmolol: 50-100 mcg/kg/min IV (if haemodynamically unstable)
   • Contraindication: Decompensated heart failure (use diltiazem instead)

4. Glucocorticoids:

   • Hydrocortisone: 100 mg IV 8-hourly or
   • Dexamethasone: 2 mg IV 6-hourly
   • Rationale: Blocks T4→T3 conversion, treats relative adrenal insufficiency

E. Supportive Care:

• Treat heart failure: Diuretics, inotropes
• Treat atrial fibrillation: Rate control (beta-blockers), anticoagulation
• Nutrition: High-calorie, high-protein (extreme catabolism)
• Vitamins: Thiamine (risk of Wernicke's if malnourished)

F. Emerging/Rescue Therapies:

• Plasmapheresis or dialysis: If refractory to medical therapy (removes circulating thyroid hormones)
• Cholestyramine: 4 g PO QDS (binds thyroid hormones in gut, interrupts enterohepatic circulation)
• Emergency thyroidectomy: If all medical options failed (rarely required)

Monitoring:

• Continuous cardiac monitoring
• Hourly vital signs
• TFTs (daily initially) - note: May not normalise for days
• Serial troponin, LFTs (myocardial infarction, hepatic dysfunction can occur)

Outcome:

• Mortality: 10-30% [33]
• Survivors: Require definitive treatment (RAI or surgery) once recovered

---

Atrial Fibrillation in Graves' Disease

Prevalence: 10-25% of patients with thyrotoxicosis [18]

Risk Factors:

• Older age (> 60 years)
• Male sex
• Severe thyrotoxicosis (fT4 > 40 pmol/L)
• Pre-existing heart disease

Mechanism:

• Thyroid hormones increase atrial ectopy and shorten refractory period
• Increased sympathetic activity

Management:

Rate Control:

• Beta-blockers (first-line): Metoprolol 50-100 mg BD or Bisoprolol 5-10 mg OD
• Calcium channel blockers (if beta-blocker contraindicated): Diltiazem 60 mg TDS

Anticoagulation: [18]

• CHA₂DS₂-VASc score to assess stroke risk
• Thyrotoxicosis itself is a risk factor (hypercoagulable state)
• Consider anticoagulation if CHA₂DS₂-VASc ≥1 in men or ≥2 in women
• DOAC or warfarin (both effective)

Cardioversion:

• Not first-line (high recurrence rate until euthyroid)
• Consider once euthyroid for 3-6 months if AF persists

Spontaneous Reversion:

• 60% revert to sinus rhythm once euthyroid [18]
• More likely if AF onset less than 1 year and no structural heart disease

---

Thyrotoxic Periodic Paralysis (TPP)

Epidemiology:

• Rare in Caucasians, more common in Asian males (Chinese, Japanese, Thai)
• Affects 2% of Asian males with thyrotoxicosis
• Male:female ratio 20:1

Pathophysiology:

• Thyroid hormone excess → Increased Na⁺/K⁺-ATPase activity → Intracellular K⁺ shift → Hypokalaemia

Clinical Features:

• Sudden onset flaccid paralysis (typically proximal lower limbs, can be all limbs)
• Onset: Often nocturnal or early morning
• Triggers: High-carbohydrate meal, alcohol, strenuous exercise
• Duration: Hours to days (resolves spontaneously)
• Reflexes: Reduced or absent
• Sensation: Intact

Investigations:

• Hypokalaemia (often severe, K⁺ less than 2.5 mmol/L)
• ECG: U waves, T wave flattening, prolonged QT (hypokalaemia)
• Normal CK (distinguishes from rhabdomyolysis)

Management:

• Acute:
  • "Potassium replacement (cautious, oral preferred): 10-20 mmol/h"
  • Avoid excessive replacement (rebound hyperkalaemia once paralysis resolves)
  • "Beta-blockers (reduce Na⁺/K⁺-ATPase activity): Propranolol 40 mg TDS"
• Long-term:
  • Treat thyrotoxicosis (prevents recurrence)
  • Beta-blockers until euthyroid
• Prevention:
  • Avoid triggers (low-carbohydrate diet, avoid alcohol)

---

Osteoporosis and Fracture Risk

Mechanism: [19]

• Thyroid hormones stimulate osteoclast activity → Increased bone resorption
• Net bone loss, particularly cortical bone

Fracture Risk:

• Increased in both subclinical and overt thyrotoxicosis
• Hip and vertebral fractures most common
• Risk persists for years after treatment

Prevention:

• Achieve euthyroidism promptly
• DEXA scan if:
  • Prolonged untreated thyrotoxicosis (> 6 months)
  • Postmenopausal women
  • Other osteoporosis risk factors
• Bisphosphonates if osteoporosis confirmed (T-score < -2.5)
• Calcium and vitamin D supplementation
• Weight-bearing exercise, smoking cessation

---

11. Prognosis and Long-Term Outcomes

Natural History

Untreated:

• Progressive thyrotoxicosis
• Cardiovascular complications (AF, heart failure)
• Risk of thyroid storm (mortality 10-30%)
• Ophthalmopathy progression (25-50%)

With Treatment:

Antithyroid Drugs: [8]

• Remission: 40-60% after 12-18 month course
• Relapse: 40-60% (typically within first year after stopping ATD)
• Long-term outcomes (25-year follow-up):
  • ~50% require definitive treatment (RAI or surgery) eventually
  • ~25% remain in remission after one course of ATD
  • ~25% have intermittent relapses managed with repeated ATD courses

Radioiodine: [26]

• Success: 70-90% cured with single dose
• Hypothyroidism: 80-90% develop within first year (lifelong levothyroxine)
• Long-term thyroid cancer risk: No increased risk demonstrated
• Ophthalmopathy: 15-20% worsening (mitigated by glucocorticoids, smoking cessation)

Surgery: [27]

• Success: > 95% cured
• Hypothyroidism: > 99% (total thyroidectomy)
• Complications: Permanent RLN injury 1-2%, permanent hypoparathyroidism 1-3%
• Long-term satisfaction: High (rapid definitive cure)

Quality of Life

During Active Disease:

• Significantly impaired (anxiety, fatigue, palpitations, sleep disturbance)
• Ophthalmopathy major contributor to reduced QoL (cosmetic, functional visual impact)

After Treatment:

• Most patients return to near-normal QoL once euthyroid
• Persistent symptoms in 10-20%:
  • Fatigue
  • Cognitive difficulties
  • Mood disturbance
  • May be related to hypothyroidism post-treatment (optimise levothyroxine)

Ophthalmopathy Outcomes

Natural History:

• Rundle's curve: [3]
  • "Active inflammatory phase: 6-24 months (CAS high)"
  • "Plateau phase: Months to years"
  • "Inactive fibrotic phase: CAS low, but structural changes persist"

With Treatment:

• 70-80% respond to immunosuppression (if active disease)
• Inactive disease requires surgical rehabilitation
• Vision-threatening complications (less than 5%): Excellent outcomes with prompt treatment (high-dose steroids, decompression)

---

12. Key Clinical Pearls

For MRCP / Postgraduate Examinations

Diagnosis:

1. TRAb is > 95% sensitive and specific for Graves' Disease [2]

   • If TRAb positive, radioiodine scan usually unnecessary

2. Thyroid bruit is pathognomonic for Graves' (indicates hypervascular gland) [5]

   • Not heard in toxic nodular goitre or thyroiditis

3. Lid retraction (sympathetic overactivity) occurs in all causes of thyrotoxicosis

   • Proptosis is specific to Graves' (autoimmune orbital inflammation) [3]

4. T3 toxicosis (isolated T3 elevation, normal T4):

   • Occurs in 5-10% of Graves' cases, particularly early or in iodine deficiency
   • Still requires treatment

Management:

5. Block-and-replace contraindicated in pregnancy [30]

   • Levothyroxine crosses placenta poorly, but thionamides cross readily → Fetal hypothyroidism

6. Propylthiouracil in first trimester, switch to carbimazole thereafter [30]

   • Carbimazole teratogenic in first trimester (aplasia cutis, choanal atresia)
   • PTU hepatotoxic with prolonged use

7. Agranulocytosis patient education is MANDATORY [23]

   • "Sore throat, fever, mouth ulcers → STOP drug, urgent blood count"
   • Mortality 5-10% if delayed recognition

8. Radioiodine worsens ophthalmopathy in 15-20% [25]

   • Give prophylactic prednisolone if mild-moderate GO
   • Avoid RAI entirely if severe active GO (CAS ≥3)

9. Smoking increases Graves' ophthalmopathy risk 8-fold [13]

   • Smoking cessation is ESSENTIAL counselling point

10. Iodine (Lugol's) must be given ≥1 hour AFTER thionamide in thyroid storm [33]

    • If given first, can worsen thyrotoxicosis (Jod-Basedow effect)

Common Exam Vignettes

Vignette 1: Sore Throat on Carbimazole

"A 35-year-old woman on carbimazole for Graves' disease presents with sore throat and fever. What is the most appropriate next step?"

Answer: Urgent FBC (within 24 hours)

• Stop carbimazole immediately
• Suspect agranulocytosis until proven otherwise
• If neutrophils less than 0.5, urgent haematology review, G-CSF, antibiotics
• Do NOT restart thionamide (definitive treatment with RAI or surgery once recovered)

Vignette 2: Pregnancy in Graves' Disease

"A 28-year-old pregnant woman at 8 weeks' gestation has newly diagnosed Graves' disease. Which antithyroid drug should be started?"

Answer: Propylthiouracil (PTU)

• First trimester: PTU preferred (lower teratogenic risk than carbimazole)
• Switch to carbimazole at 14-16 weeks (after organogenesis, to avoid PTU hepatotoxicity)
• Target fT4 upper limit of normal (minimise fetal ATD exposure)
• Monitor TRAb at 18-22 weeks and 30-34 weeks (fetal thyrotoxicosis risk)

Vignette 3: Post-RAI Ophthalmopathy

"A 45-year-old smoker with mild Graves' ophthalmopathy is planned for radioiodine therapy. What should be co-administered to reduce risk of worsening eye disease?"

Answer: Prophylactic glucocorticoids (prednisolone 0.3-0.5 mg/kg daily for 1 month, taper over 3 months) [25]

• Reduces risk of RAI-induced ophthalmopathy worsening by 60%
• Also essential: Smoking cessation counselling

Vignette 4: Thyroid Storm

"A 50-year-old with known Graves' disease presents with fever (40°C), confusion, HR 150, and diarrhoea following a chest infection. Diagnosis: thyroid storm. Management?"

Answer (multi-step):

1. Resuscitation: IV fluids, cooling, antibiotics
2. PTU 200 mg PO 4-hourly (blocks synthesis AND conversion)
3. Wait 1 hour, then Lugol's iodine 10 drops TDS (blocks release)
4. Propranolol 40-80 mg PO 4-6 hourly (blocks conversion, symptom control)
5. Hydrocortisone 100 mg IV 8-hourly (blocks conversion, adrenal support)
6. ICU/HDU admission

Vignette 5: Atrial Fibrillation in Thyrotoxicosis

"A 65-year-old man with Graves' disease has new-onset AF. Cardioversion is attempted but AF recurs. What is the most appropriate next step?"

Answer: Achieve euthyroidism first

• 60% of thyrotoxic AF reverts spontaneously once euthyroid [18]
• Cardioversion has high recurrence rate until euthyroid
• Rate control (beta-blockers) and anticoagulation in interim
• Reassess for cardioversion after 3-6 months of euthyroidism

---

13. Patient Explanation (Layperson Layer)

What is Graves' Disease?

Graves' Disease is a condition where your immune system mistakenly produces an antibody that "switches on" your thyroid gland continuously, like a car with the accelerator stuck down. This causes your thyroid to produce too much thyroid hormone, making your metabolism run too fast.

The thyroid gland is a butterfly-shaped gland in your neck that controls your body's metabolism—how fast you burn energy.

What are the symptoms?

When your thyroid is overactive, you may experience:

• Weight loss despite eating normally or more
• Feeling hot and sweating excessively
• Fast heartbeat or palpitations
• Shaking hands (tremor)
• Anxiety and difficulty sleeping
• More frequent bowel movements
• Fatigue and muscle weakness
• Irregular periods (women)

Some people also develop:

• Bulging eyes (Graves' eye disease) - about 1 in 4 people
• Swollen, bumpy skin on the shins (rare)

What causes it?

The exact cause isn't fully understood, but it involves:

• Genetics: It runs in families
• Environmental triggers: Stress, smoking, pregnancy, or infections may trigger it in people who are genetically susceptible
• More common in women (5-10 times more than men)

How is it diagnosed?

• Blood tests: Thyroid hormone levels (T3, T4) are high, and TSH (the brain's signal to the thyroid) is very low
• Antibody test: TRAb antibody is positive in 95% of cases (confirms Graves')
• Ultrasound or scan (sometimes): Shows an enlarged, overactive thyroid gland

How is it treated?

There are three main treatment options:

1. Tablets (Antithyroid Drugs - Carbimazole or Propylthiouracil)

• Take for 12-18 months
• Reduces thyroid hormone production
• Side effects: Rash (common), sore throat (rare but serious - call doctor immediately if this happens)
• 50% chance of permanent cure; 50% chance it comes back

2. Radioiodine (Radioactive Iodine)

• Swallow a capsule that slowly destroys the overactive thyroid over months
• Simple, single treatment
• Cannot be used in pregnancy or breastfeeding (avoid pregnancy for 6 months after)
• Can worsen eye problems (if you have bulging eyes, inform your doctor)
• Results in underactive thyroid (you'll need thyroid hormone tablets lifelong)

3. Surgery (Thyroidectomy)

• Remove the thyroid gland
• Rapid cure
• Risks: Hoarse voice (1-2%), low calcium (1-3%)
• Results in underactive thyroid (lifelong thyroid hormone tablets)

Which treatment is right for me?

Your doctor will discuss options based on:

• Your age and whether you plan to become pregnant
• Size of your thyroid gland
• Whether you have eye problems
• Your preference

Will I get better?

Yes, with treatment, most people feel completely back to normal.

• Treatment controls the overactive thyroid
• If tablets work and you stay in remission, you may not need further treatment
• If tablets don't work long-term, radioiodine or surgery provide a permanent cure
• If you develop an underactive thyroid (common after radioiodine or surgery), daily thyroid hormone tablets replace what your body needs—most people feel well on this

What about my eyes?

If you have bulging eyes (Graves' eye disease):

• Stop smoking (most important - smoking makes eye problems much worse)
• Mild cases: Artificial tears, sunglasses
• Moderate-severe cases: Steroid treatment or surgery may be needed
• Urgent treatment needed if vision affected

Important warnings:

1. If you take carbimazole and develop a sore throat, fever, or mouth ulcers → STOP the tablets and see a doctor urgently for a blood test (risk of serious infection)

2. If pregnant or planning pregnancy:

   • Inform your doctor immediately
   • Different tablets needed in pregnancy
   • Close monitoring required

3. Smoking makes eye problems much worse - stopping smoking is crucial

Long-term outlook:

With treatment, the outlook is excellent. Most people return to normal health. The key is finding the right treatment for you and regular monitoring.

---

14. Evidence and Guidelines

Major Guidelines

Evidence-Based Recommendations

---

15. References

1. Morshed S, Latif R, Davies TF. Signal responses to neutral TSH receptor antibody - A cycle of damage in the pathophysiology of Graves' disease. J Autoimmun. 2023;136:103027. PMID: 36898184

2. Ehlers M, Allelein S, Schott M. TSH-receptor autoantibodies: pathophysiology, assay methods, and clinical applications. Minerva Endocrinol. 2018;43(3):323-332. PMID: 29265783

3. Wiersinga WM, Eckstein A, Žarković M. Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025;13(1):64-80. PMID: 40324443

4. Hoang TD, Stocker DJ, Chou EL, et al. 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022;51(2):287-304. PMID: 35662442

5. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155-1166. PMID: 22394559

6. Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387. PMID: 32107168

7. Orgiazzi J. Thyroid autoimmunity. Presse Med. 2012;41(12 Pt 2):e611-e625. PMID: 23164679

8. Meling Stokland TS, Austdal M, Nedrebø BG, et al. Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. J Clin Endocrinol Metab. 2024;109(2):e618-e626. PMID: 37747433

9. Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387. PMID: 32107168

10. Mooij CF, Cheetham T, Verburg FA, et al. 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022;11(1):e210073. PMID: 34981748

11. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155-1166. PMID: 22394559

12. Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387. PMID: 32107168

13. Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993. PMID: 33329408

14. Lane LC, Wood CL, Cheetham TD. Graves' disease: moving forwards. Arch Dis Child. 2023;108(2):81-86. PMID: 35831126

15. Antonelli A, Ferrari SM, Ragusa F, et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387. PMID: 32107168

16. Morshed S, Latif R, Davies TF. Signal responses to neutral TSH receptor antibody - A cycle of damage in the pathophysiology of Graves' disease. J Autoimmun. 2023;136:103027. PMID: 36898184

17. Bartalena L, Gallo D, Tanda ML, et al. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors. Ophthalmic Plast Reconstr Surg. 2023;39(4S Suppl 1):S2-S9. PMID: 38054980

18. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821):1155-1166. PMID: 22394559

19. Siderova M, Hristozov K, Tsukeva V, et al. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy. Arch Endocrinol Metab. 2018;62(3):288-294. PMID: 29768627

20. Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1439-1470. PMID: 36480280

21. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. PMID: 27521067 (Guideline, not in PubMed search above but essential reference)

22. Lane LC, Cheetham TD. Graves' disease: developments in first-line antithyroid drugs in the young. Expert Rev Endocrinol Metab. 2020;15(2):89-99. PMID: 32133893

23. Yu S, Wu L, Li B, et al. SIDE EFFECTS OF PTU AND MMI IN THE TREATMENT OF HYPERTHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS. Endocr Pract. 2020;26(2):207-217. PMID: 31652102

24. Yoshimura Noh J, Inoue T, Suzuki M, et al. Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil. Endocr J. 2024;71(6):607-613. PMID: 38710619

25. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. PMID: 34297684

26. Ma C, Xie J, Wang H, et al. Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev. 2016;2:CD010094. PMID: 26891370

27. Mu W, Ren L, Xu B, et al. Total versus near-total thyroidectomy in Graves' disease: a systematic review and meta-analysis of comparative studies. Gland Surg. 2021;10(3):1122-1134. PMID: 33708555

28. Sharabati E, Qafesha R, Hindawi N, et al. The efficacy and safety of selenium supplementation versus placebo in the treatment of Graves' orbitopathy: A systematic review and meta-analysis of randomised controlled trials. Clin Endocrinol (Oxf). 2024;101(5):434-445. PMID: 39138905

29. Ahn HY, Lee SY, Jung SH, et al. Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial. JAMA Ophthalmol. 2025;143(1):17-25. PMID: 40014353

30. Lee SY, Pearce EN. Testing, Monitoring, and Treatment of Thyroid Dysfunction in Pregnancy. J Clin Endocrinol Metab. 2021;106(3):883-892. PMID: 33349844

31. Kobaly K, Mandel SJ. Hyperthyroidism and Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):533-545. PMID: 31345521

32. Samuels SL, Namoc SM, Bauer AJ. Neonatal Thyrotoxicosis. Clin Perinatol. 2018;45(1):31-40. PMID: 29406005

33. De Almeida JP, McCalmon S, Cabandugama PK. Clinical Review and Update on the Management of Thyroid Storm. Mo Med. 2022;119(5):439-444. PMID: 36118802

---

16. Summary: High-Yield Points for Revision

Definition:

• Autoimmune hyperthyroidism due to TSH receptor-stimulating antibodies (TRAb)
• Most common cause of sustained thyrotoxicosis (60-80%)

Unique Features:

• Diffuse goitre with bruit
• Graves' ophthalmopathy (25-50%)
• Pretibial myxoedema (1-5%)

Diagnosis:

• Low TSH, high T3/T4
• TRAb positive (95%) - diagnostic
• Diffuse high uptake on scan

Treatment Options:

1. Antithyroid drugs (12-18 months): 40-60% remission
2. Radioiodine: 70-90% cure, causes hypothyroidism
3. Surgery: > 95% cure, risks RLN injury/hypoparathyroidism

Pregnancy:

• PTU first trimester, carbimazole second/third
• Monitor TRAb (fetal thyrotoxicosis risk)
• No block-and-replace

Emergencies:

• Agranulocytosis: Sore throat → Stop drug, urgent FBC
• Thyroid storm: High fever, tachycardia, confusion → PTU + iodine (1h later) + propranolol + steroids
• Optic neuropathy: Vision loss → Urgent steroids + decompression

Ophthalmopathy:

• Smoking cessation (most important)
• IV steroids for active moderate-severe (CAS ≥3)
• RAI can worsen (give prophylactic steroids)

Exam Traps:

• Lid retraction = all thyrotoxicosis; Proptosis = Graves' only
• TRAb predicts relapse
• Iodine AFTER thionamide in storm
• Total > subtotal thyroidectomy

---

Word Count: ~9,800 words
Line Count: ~1,000 lines
Citations: 33 (25 unique PubMed references + key guidelines)